KLBF:IDX
Kalbe Farma Tbk PT
IDRÂ 720.00
arrow_downward
-1.37%(-10.00) 1D
Oct 1, 4:14:38 PM GMT+7 · IDR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KLBF...
Open
IDRÂ 720
High
IDRÂ 730
Low
IDRÂ 715
Mkt. cap
33.71T
Avg. vol.
71.89M
Volume
46.87M
Dividend
2.78%
Quarterly dividend
IDRÂ 5
Ex-dividend date
Jun 4, 2026
P/E ratio
9.05
52-wk high
IDRÂ 1,345
52-wk low
IDRÂ 630
EPS
IDRÂ 80
Shares outstanding
46.81B
No. of employees
13K
Open
IDRÂ 720
High
IDRÂ 730
Low
IDRÂ 715
Mkt. cap
33.71T
Avg. vol.
71.89M
Volume
46.87M
Dividend
2.78%
Quarterly dividend
IDRÂ 5
Ex-dividend date
Jun 4, 2026
P/E ratio
9.05
52-wk high
IDRÂ 1,345
52-wk low
IDRÂ 630
EPS
IDRÂ 80
Shares outstanding
46.81B
No. of employees
13K
News stories
From web sources and news partners
AD HOC NEWS
·
15 hours ago
Kalbe Farma stock reports 14.00 percent revenue growth as margins slip
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
Last report
Jul 28, 2026
Fiscal period
Q2 2026
EPS / Est. (IDR)
IDRÂ 19.68 / IDRÂ 19.46
+1.15%beat
arrow_upward
Revenue / Est. (IDR)
9.80T / -
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in IDR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 8.91T | 9.34T | 9.68T | 9.80T |
Cost of goods sold | 5.46T | 5.92T | 6.02T | 6.25T |
Cost of revenue | 5.46T | 5.92T | 6.02T | 6.25T |
Research and development expenses | 98.31B | 160.88B | 113.14B | 122.60B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.51T | 1.95T | 2.23T | 2.27T |
Operating expense | 2.60T | 2.14T | 2.33T | 2.39T |
Total operating expenses | 8.06T | 8.05T | 8.36T | 8.64T |
Operating income | 851.77B | 1.28T | 1.32T | 1.16T |
Other non operating income | -3.78B | -4.17B | -3.63B | -3.74B |
EBT including unusual items | 877.87B | 1.30T | 1.36T | 1.19T |
EBT excluding unusual items | 888.55B | 1.30T | 1.36T | 1.18T |
Income tax expense | 211.19B | 252.81B | 303.84B | 271.57B |
Effective tax rate | 24.06% | 19.41% | 22.40% | 22.80% |
Other operating expenses | -7.23B | 31.35B | -10.02B | 2.13B |
Net income | 656.41B | 1.03T | 1.03T | 890.54B |
Net profit margin | 7.37% | 11.07% | 10.63% | 9.09% |
Earnings per share | 14.44 | 22.72 | 22.74 | 19.68 |
Interest and investment income | 41.31B | 40.43B | 32.07B | 43.61B |
Interest expense | -9.69B | -5.77B | -4.61B | -6.78B |
Net interest expenses | 31.62B | 34.66B | 27.46B | 36.83B |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.05T | 1.45T | 1.51T | 1.20T |
Gain or loss from assets sale | - | - | - | - |